| [1] |
Lu J, Zhang XP, Zhong BY, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west[J]. Lancet Gastroenterol Hepatol, 2019, 4(9): 721-730.
|
| [2] |
Basit SA, Stone CD, Gish R. Portal vein thrombosis[J]. Clin Liver Dis, 2015, 19(1): 199-221.
|
| [3] |
Chan SL, Chong CC, Chan AW, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016[J]. World J Gastroenterol, 2016, 22(32): 7289-7300.
|
| [4] |
Gao Y, Wang PX, Cheng JW, et al. Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis[J]. Cancer Med, 2019, 8(16): 6933-6944.
|
| [5] |
Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies[J]. Semin Liver Dis, 2018, 38(3): 242-251.
|
| [6] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19(1): 1-20.
|
| [7] |
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599, e1.
|
| [8] |
Borsig L. Heparin as an inhibitor of cancer progression[J]. Prog Mol Biol Transl Sci, 2010, 93: 335-349.
|
| [9] |
Linhardt RJ. Heparin-induced cancer cell death[J]. Chem Biol, 2004, 11(4): 420-422.
|
| [10] |
程树群，吴孟超，陈汉, 等. 胸腺肽α1对原发性肝癌术后复发的影响[J]. 中华肝胆外科杂志, 2004, 10(9): 592-593.
|